Extract from the above information

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

Myocardial protection, vasodilation, anti-atherosclerosis, anti-thrombosis, improvement of microcirculation, regulation of tissue repair and regeneration, anti-bacterial and anti-inflammatory, anti-tumor, and anti-oxidation

It has local analgesic effect and antiseptic effect

In accordance with the requirements of the "Non-clinical Research Management Standards for Drugs", multiple tests on mice, guinea pigs and cats have shown that this product has no abnormal toxic reactions, meets the requirements of antihypertensive substances, has no allergic reactions, and has not caused animal deaths at high doses.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.